Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases
- PMID: 30255310
- PMCID: PMC6397666
- DOI: 10.1007/s40262-018-0712-z
Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases
Abstract
Background: Hydroxychloroquine is an oral drug prescribed to pregnant women with rheumatic disease to reduce disease activity and prevent flares. Physiologic changes during pregnancy may substantially alter drug pharmacokinetics. However, the effect of pregnancy on hydroxychloroquine disposition and the potential need for dose adjustment remains virtually unknown.
Methods: We performed a population-pharmacokinetic analysis using samples from the Duke Autoimmunity in Pregnancy Registry from 2013 to 2016. We measured hydroxychloroquine concentration using high-performance liquid chromatography/tandem mass spectrometry and analyzed data using non-linear mixed-effect modeling. We calculated differences between pregnancy and postpartum empirical Bayesian estimates using paired t tests. We computed steady-state concentration profiles for hydroxychloroquine during pregnancy and postpartum using individual clinical data and empirical Bayesian estimates developed from the final pharmacokinetic model.
Results: We obtained 145 serum samples from 50 patients, 25 of whom had paired pregnancy and postpartum specimens. Five subjects had average concentrations (pregnancy and postpartum) < 100 ng/mL, consistent with medication non-adherence, and were excluded. The population estimated apparent volume of distribution was 1850 L/70 kg and estimated apparent clearance was 51 L/h. Compared with postpartum, median apparent volume of distribution increased significantly during pregnancy (p < 0.001), whereas apparent clearance and 24-h area under the curve did not change.
Conclusions: We developed a one-compartment population-pharmacokinetic model for hydroxychloroquine in pregnant women with rheumatic disease. Estimates for serum CL were within the expected range for plasma in non-pregnant adults. Because CL and 24-h area under the curve did not change during pregnancy compared with postpartum, our modeling in this small cohort does not support adjusting hydroxychloroquine dose during pregnancy.
Conflict of interest statement
Conflicts of Interest:
T.P.G. has no relevant disclosures.
Figures
Similar articles
-
Population pharmacokinetics of long-term hydroxychloroquine therapy in patients with rheumatic diseases.Br J Clin Pharmacol. 2025 Feb;91(2):365-373. doi: 10.1111/bcp.16257. Epub 2024 Sep 24. Br J Clin Pharmacol. 2025. PMID: 39315408
-
Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes.J Rheumatol. 2019 Jan;46(1):57-63. doi: 10.3899/jrheum.180158. Epub 2018 Oct 1. J Rheumatol. 2019. PMID: 30275257 Free PMC article.
-
Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.Ther Drug Monit. 2016 Apr;38(2):259-67. doi: 10.1097/FTD.0000000000000261. Ther Drug Monit. 2016. PMID: 26587870
-
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.Lupus. 1996 Jun;5 Suppl 1:S11-5. Lupus. 1996. PMID: 8803904 Review.
-
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6. Inflammopharmacology. 2015. PMID: 26246395 Review.
Cited by
-
Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):703-713. doi: 10.1007/s13318-020-00648-y. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32968954 Free PMC article.
-
LC-MS/MS Method for Determination of Hydroxychloroquine and Metabolites: Application in a Pharmacokinetic Study.J Anal Methods Chem. 2022 Jan 5;2022:6058445. doi: 10.1155/2022/6058445. eCollection 2022. J Anal Methods Chem. 2022. PMID: 35003822 Free PMC article.
-
The effects of hydroxychloroquine and its promising use in refractory obstetric antiphospholipid syndrome.Rheumatol Int. 2024 Feb;44(2):223-234. doi: 10.1007/s00296-023-05457-5. Epub 2023 Sep 23. Rheumatol Int. 2024. PMID: 37741812 Free PMC article. Review.
-
Refining lupus management: a comprehensive review of HCQ blood levels.Rheumatol Adv Pract. 2025 Jul 7;9(3):rkaf080. doi: 10.1093/rap/rkaf080. eCollection 2025. Rheumatol Adv Pract. 2025. PMID: 40746405 Free PMC article. Review.
-
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.PLoS Med. 2020 Sep 3;17(9):e1003252. doi: 10.1371/journal.pmed.1003252. eCollection 2020 Sep. PLoS Med. 2020. PMID: 32881895 Free PMC article.
References
-
- Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795–810. - PubMed
-
- Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640–7. - PubMed
-
- Fischer-Betz R, Specker C, Brinks R, Aringer M, Schneider M. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 2013;52:1070–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical